1492 Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

1492 Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,733	Closed	-$615K	–	102
2019 Q2	$615K	Buy	+7,733	New	+$692K	0.58%	54
2017 Q1	–	Sell	-2,043	Closed	-$222K	–	109
2016 Q4	$222K	Sell	2,043 -83	-4%	-$9.89K	0.17%	88
2016 Q3	$350K	Buy	+2,126	New	+$335K	0.29%	70

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

1492 Capital Management's ICPT Position: Q3 2019 in Review

1492 Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 7,733 shares — an estimated $615K sold.

1492 Capital Management first reported a position in ICPT in Q3 2016 and held it in 3 quarters. The position peaked at $615K in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

1492 Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
1492 Capital Management sold 7,733 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $615K.
1492 Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
1492 Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $615K in Q2 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on 1492 Capital Management's 13F filing for Q3 2019, filed 5 Nov 2019.